Even though ThromboGenics NV decided not to seek a priority review of its BLA for its symptomatic vitreomacular adhesion (VMA) drug ocriplasmin, the FDA decided to bestow one on the company anyway. The Leuven, Belgium-based firm now plans to withdraw its original BLA and to re-submit the file in April. The fast-track procedure should lead to a decision within six months.